Endometriosis, a prevalent but debilitating condition affecting women, poses significant challenges in diagnosis and management. The current 2024 guideline, developed by the Korean Society of Endometriosis (KSE), builds upon the 2018 KSE guideline. This guideline aims to provide customized recommendations tailored to Korea’s unique clinical aspects and medical environment, and addresses key areas such as diagnosis, medical and surgical management, considerations for special populations, and its complex relationship with cancer.

Endometriosis, a prevalent but debilitating condition affecting women, poses significant challenges in diagnosis and management. The current 2024 guideline, developed by the Korean Society of Endometriosis (KSE), builds upon the 2018 KSE guideline. This guideline aims to provide customized recommendations tailored to Korea’s unique clinical aspects and medical environment, and addresses key areas such as diagnosis, medical and surgical management, considerations for special populations, and its complex relationship with cancer.

Endometriosis, a prevalent but debilitating condition affecting women, poses significant challenges in diagnosis and management. The current 2024 guideline, developed by the Korean Society of Endometriosis (KSE), builds upon the 2018 KSE guideline. This guideline aims to provide customized recommendations tailored to Korea’s unique clinical aspects and medical environment, and addresses key areas such as diagnosis, medical and surgical management, considerations for special populations, and its complex relationship with cancer.

Endometriosis, a prevalent but debilitating condition affecting women, poses significant challenges in diagnosis and management. The current 2024 guideline, developed by the Korean Society of Endometriosis (KSE), builds upon the 2018 KSE guideline. This guideline aims to provide customized recommendations tailored to Korea’s unique clinical aspects and medical environment, and addresses key areas such as diagnosis, medical and surgical management, considerations for special populations, and its complex relationship with cancer.

Endometriosis, a prevalent but debilitating condition affecting women, poses significant challenges in diagnosis and management. The current 2024 guideline, developed by the Korean Society of Endometriosis (KSE), builds upon the 2018 KSE guideline. This guideline aims to provide customized recommendations tailored to Korea’s unique clinical aspects and medical environment, and addresses key areas such as diagnosis, medical and surgical management, considerations for special populations, and its complex relationship with cancer.

Objective: Traumatic occult pneumothorax is defined as a pneumothorax that cannot be identified with a simple chest X-ray and can be detected only by chest computed tomography (CT). The purpose of this study was to retrospectively recognize the difference between thoracostomy and conservative treatment of traumatic occult pneumothorax. Methods: Among the thoracic trauma inpatients who visited a single emergency room (ER) from January 2021 to May 2022, adult patients aged over 18 years, diagnosed with traumatic pneumothorax who survived their ER stay and with abnormalities were included as the final study subjects and their histories were compared. Results: Of the total of 269 thoracic trauma patients, 110 were diagnosed with traumatic pneumothorax, of which 30 were traumatic occult pneumothorax patients. Multiple logistic regression analyses performed in the traumatic occult pneumothorax patient group showed that as the pneumothorax size increased, the probability of finding an occult pneumothorax decreased (odds ratio [OR]=0.93; 95% confidence interval [CI], 0.89-0.98). In very severe cases of rib fractures (OR=0.65; 95% CI, 0.43-0.98), the probability of detecting occult pneumothorax was reduced. Among the patients with traumatic occult pneumothorax, 15 patients underwent thoracostomy. Cases of hemothorax (70%; P=0.05), surgery (26.67%; P<0.01), and higher injury severity scores (12.87±7.69; P=0.02) were more common in the thoracostomy group. Conclusion Usually traumatic occult pneumothorax is treated conservatively with regular follow-up, but thoracostomy is necessary when it is accompanied by hemothorax and for patients requiring surgery and having a higher injury severity score.

Objective: Traumatic occult pneumothorax is defined as a pneumothorax that cannot be identified with a simple chest X-ray and can be detected only by chest computed tomography (CT). The purpose of this study was to retrospectively recognize the difference between thoracostomy and conservative treatment of traumatic occult pneumothorax. Methods: Among the thoracic trauma inpatients who visited a single emergency room (ER) from January 2021 to May 2022, adult patients aged over 18 years, diagnosed with traumatic pneumothorax who survived their ER stay and with abnormalities were included as the final study subjects and their histories were compared. Results: Of the total of 269 thoracic trauma patients, 110 were diagnosed with traumatic pneumothorax, of which 30 were traumatic occult pneumothorax patients. Multiple logistic regression analyses performed in the traumatic occult pneumothorax patient group showed that as the pneumothorax size increased, the probability of finding an occult pneumothorax decreased (odds ratio [OR]=0.93; 95% confidence interval [CI], 0.89-0.98). In very severe cases of rib fractures (OR=0.65; 95% CI, 0.43-0.98), the probability of detecting occult pneumothorax was reduced. Among the patients with traumatic occult pneumothorax, 15 patients underwent thoracostomy. Cases of hemothorax (70%; P=0.05), surgery (26.67%; P<0.01), and higher injury severity scores (12.87±7.69; P=0.02) were more common in the thoracostomy group. Conclusion Usually traumatic occult pneumothorax is treated conservatively with regular follow-up, but thoracostomy is necessary when it is accompanied by hemothorax and for patients requiring surgery and having a higher injury severity score.

Background: The benefits of transradial access (TRA) over transfemoral access (TFA) for bifurcation percutaneous coronary intervention (PCI) are uncertain because of the limited availability of device selection. This study aimed to compare the procedural differences and the in-hospital and long-term outcomes of TRA and TFA for bifurcation PCI using secondgeneration drug-eluting stents (DESs). Methods: Based on data from the Coronary Bifurcation Stenting Registry III, a retrospective registry of 2,648 patients undergoing bifurcation PCI with second-generation DES from 21 centers in South Korea, patients were categorized into the TRA group (n = 1,507) or the TFA group (n = 1,141). After propensity score matching (PSM), procedural differences, in-hospital outcomes, and device-oriented composite outcomes (DOCOs; a composite of cardiac death, target vessel-related myocardial infarction, and target lesion revascularization) were compared between the two groups (772 matched patients each group). Results: Despite well-balanced baseline clinical and lesion characteristics after PSM, the use of the two-stent strategy (14.2% vs. 23.7%, P = 0.001) and the incidence of in-hospital adverse outcomes, primarily driven by access site complications (2.2% vs. 4.4%, P = 0.015), were significantly lower in the TRA group than in the TFA group. At the 5-year follow-up, the incidence of DOCOs was similar between the groups (6.3% vs. 7.1%, P = 0.639). Conclusion The findings suggested that TRA may be safer than TFA for bifurcation PCI using second-generation DESs. Despite differences in treatment strategy, TRA was associated with similar long-term clinical outcomes as those of TFA. Therefore, TRA might be the preferred access for bifurcation PCI using second-generation DES.

In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.